1Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol, 2002, 46 ( 1 ): 1 - 23.
2Martin A, Gutierrez E, Muglia J,et al. A multicenter dose-escalation trial with denileukin diftitox ( ONTAK, DAB (389) IL - 2 ) in patients with severe psoriasis. J Am Acad Dermatol, 2001,45 (6) :871 -881.
3da Silva AJ, Brickelmaier M, Majeau GR, et al. Al efacept, an immunomodulatory recombinant LFA - 3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16 - dependent apoptosis of CD2 ( + ) cells. J Immunol, 2002, 168(9) :4462 -4471.
4Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by sc lective targeting of memory effector T lymphocytes. N Engl J Med, 2001, 345(4) :248 -255.
5Lebwohl M. New developments in the treatment of psoriasis. Arch Dermatol, 2002, 138 (5) :686 - 688.
6Branco L, Barren P, Mao SY, et al. Selective deletion of antigen-spe cific, activated T cells by a humanized MAB to CD2 ( MEDI - 507 ) is mediated by NK cells. Transplantation, 1999,68(10) :1588 - 1596.
7Chau LA, Tso JY, Melrose J, et al. HuM291 (Nuvion), a humanized Fc receptor-nonbinding antibody against CD3, anergizes peripheral blood T cells as partial agonist of the T cell receptor. Transplantation, 2001, 71(7) :941 -950.
8Gottlieb AB, Krueger JG, Wittkowski K, et al. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11 a antibody. Arch Dermatol, 2002, 138(5) :591 -600.
9Singri P, West DP, Gordon KB. Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol, 2002, 138(5) :657 -663.
10Gotflieb AB, Lebwohl M, Shirin S,et al. Anti-CD4 monoclonal anti body treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol, 2000, 43(4) :595 -604.
